IPO FACT SHEET

IPO : Symbiotec Pharmalab Limited August 2026

Snapshot

Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company with capabilities across organic chemistry, biotechnology and complex injectables. With over 30 years of industry experience, the company has developed a vertically integrated manufacturing platform focused on APIs, particularly corticosteroid and steroidal-hormone APIs. It has a portfolio of over 60 corticosteroid and steroidal-hormone APIs and operates fermentation and complex chemical synthesis capabilities. Symbiotec serves more than 200 customers across over 40 countries and has regulatory approvals and filings in major global markets, including the US and Europe.

Opening Date	Monday, August 24, 2026
Closing Date	Thursday, August 27, 2026
Price Band	Rs. 938 to 988 per share
Bid Lot	15 Shares
Issue Size	1,77,86,442 shares (aggregating up to Rs. 1,757 Cr)
Fresh Issue	15,21,261 shares (aggregating up to Rs. 150 Cr)
Offer for Sale	1,62,65,181 shares (aggregating up to Rs. 1,607 Cr)
Registrar	MUFG Intime India Pvt.Ltd.

Company Vision

Symbiotec Pharmalab's vision is to build a globally recognised, science-driven pharmaceutical and biotechnology platform by combining advanced chemistry, biotechnology and complex injectable capabilities. The company aims to strengthen its position in corticosteroid and steroidal-hormone APIs while expanding into specialised fermentation, biotechnology and high-value pharmaceutical products. Its R&D focus is directed towards developing complex APIs, improving manufacturing processes and adopting technologies such as biotransformation and precision fermentation. The company also seeks to maintain strong regulatory standards, backward integration and sustainable manufacturing practices while serving customers across international markets.

Key Financials

Amount in cr.	FY2026	FY2025	FY2024
Assets	1,781	1,580	1,295
Total Income	872	756	723
Profit After Tax	110	97	100
EBITDA	231.97	206.11	177.04
NET Worth	1,159	821	721
Reserves and Surplus	1,146	810	710
Total Borrowing	388	541	247

Growth Prospects

Symbiotec has meaningful growth opportunities from rising global demand for corticosteroid, steroidal-hormone and fermentation-based APIs. The company's presence across major API molecules, backward-integrated manufacturing capabilities and regulatory approvals provide a strong platform for expansion. Its customer base of more than 200 customers across over 40 countries also supports international growth. The company can further benefit from increasing demand in therapeutic areas such as oncology, immunosuppressants, respiratory care and hormonal therapies. Expansion of its R&D pipeline, CDMO services, fermentation capabilities and complex injectable portfolio could provide additional avenues for future growth.

Risk Assessment

Symbiotec's business carries risks arising from its high dependence on API sales, particularly its key corticosteroid and steroidal-hormone products. Its top five APIs contributed a significant portion of revenue, making demand fluctuations or production disruptions important risks. The company also operates in a highly regulated industry where compliance with US FDA, EU-GMP and other regulatory requirements involves significant costs and operational complexity. Fermentation-based manufacturing can face contamination, batch variability and scale-up challenges. Additionally, dependence on specialised manufacturing processes, regulatory approvals and international markets could affect operations if compliance issues, supply disruptions or changes in customer demand arise.